FILE:JNJ/JNJ-8K-20100205164333.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
 
 
 
 
 
Item 8.01.  Other Events.
On January 20, 2010, the Company issued a press release to announce the completion of the acquisition by Ethicon, Inc., a subsidiary of the Company, of Acclarent, Inc., a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat, for a purchase price of approximately $785 million.  The transaction is expected to have a dilutive impact to the Company's 2010 adjusted earnings per share of approximately $0.03 to $0.04.  The Companys press release is attached to this Report as Exhibit 99.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

Exhibit 99.1
Contact:
Ethicon, Inc.   
Barbara Montresor                                                                          
732-865-2488 (mobile)     
                                                              
                            
J&J Corporate Communications
Bill Price
732-524-6623 (office)
732-668-3735 (mobile)
 
Louise Mehrotra
J&J Investor Relations
732-524-6491
Stan Panasewicz
732-524-2524
 
SOMERVILLE, N.J., Jan 20, 2010 -- Ethicon, Inc., announced today that it has completed the acquisition of Acclarent, Inc., following clearance under the Hart-Scott-Rodino Antitrust Improvement Act.  Acclarent is a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT).  Ethicon announced its agreement to acquire Acclarent on December 16, 2009.
"By bringing together the strengths and experiences of the two companies, we create a unique way to innovate in the surgical ENT space," said Gary Pruden, Johnson & Johnson Company Group Chairman with responsibility for Ethicon.  "The surgical ENT market is underpenetrated and there is opportunity to help more patients restore their quality of life with less-invasive surgical solutions.  We look forward to working with Acclarent and its customers to do this."
About Ethicon
Ethicon, Inc., a Johnson & Johnson company, is a trusted, world-wide leader in surgical care.  For over a century, Ethicon has continuously introduced innovations in wound closure, general surgery, wound management, women's health and urology and aesthetic medicine that fulfill the Company's vision: Restoration of body and of life.  For more information, visit .
www.ethicon.com


